Filing Analysis
The Oncology Institute, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release furnished in this filing.
Key Facts
- The filing reports financial results for the three months ended March 31, 2026.
- The information is furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results is included as Exhibit 99.1.
- The report was signed by Robert Carter, the Chief Financial Officer, on May 7, 2026.
The Oncology Institute, Inc. furnished an updated investor presentation dated March 13, 2026, for use in upcoming investor meetings. The filing is a routine disclosure under Regulation FD to ensure public access to information shared with private investors.
Key Facts
- The company furnished an investor presentation as Exhibit 99.1 on March 13, 2026.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
- The report was signed by Robert Carter, the Chief Financial Officer.
- The company's common stock (TOI) and redeemable warrants (TOIIW) are listed on the Nasdaq Stock Market.
The Oncology Institute, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The information was provided via a press release furnished as an exhibit to the filing.
Key Facts
- The report covers financial results for the quarter and fiscal year ended December 31, 2025.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The press release is included as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
The Oncology Institute, Inc. appointed Kimberly Tzoumakas to its Board of Directors effective February 23, 2026. Ms. Tzoumakas is an independent director who will receive standard non-employee director compensation including a $75,000 annual retainer and future RSU grants.
Key Facts
- Kimberly Tzoumakas appointed to the Board effective February 23, 2026
- Director meets Nasdaq independence requirements
- Annual cash compensation of $75,000 plus future RSU grants
- No reportable related-party transactions or conflicts of interest identified